Advanced Viral Research Corp. Announces European Patent Approval for AVR118

YONKERS, NY--(Marketwire - April 14, 2008) - Advanced Viral Research Corp. (OTCBB: ADVR), announced today that it has been granted a European patent for the use of AVR118 in the treatment of AIDS patients. The ADVR application number 98915562, “Combination of Product R and an Antiviral Agent in the Therapy of HIV Infections,” was published in the European Patent Bulletin No 08/02 on January 9, 2008.

MORE ON THIS TOPIC